Skip to main content
Evergreen Ledger

SSB 5917

Signed

Senate

Abortion medications

Improving access to abortion medications.

How does a bill become law?
  1. Introduced: The bill is filed and assigned a number.
  2. Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
  3. Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
  4. Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
  5. Governor: The Governor reviews the bill and decides whether to sign or veto it.
  6. Signed: The bill has been signed into law.
Introduced: January 26, 2026
Last Action: March 14, 2026
Status: C 52 L 26
View Bill Text (HTML) (opens in new tab)View Bill Text (PDF) (opens in new tab)

AI Analysis

This analysis was generated by AI and may contain errors. It is not legal advice. Always refer to the official bill text for authoritative information.
People & CommunitiesPeople-leaningCorporate & Wealthy Interests

This bill expands the authority of the Washington State Department of Corrections to distribute abortion medications like mifepristone and misoprostol to health care providers and entities across the state, including those outside the correctional system. It allows the department to operate a distribution program, charge a $5 fee per dose to cover logistics, and bypass the need for a wholesaler’s license for this specific activity.

  • Authorizes the Department of Corrections (DOC) to acquire, dispense, deliver, and distribute abortion medications—including mifepristone and misoprostol—as part of its authority.
  • Allows the DOC to provide these medications to health care providers and entities (e.g., clinics, hospitals, pharmacies) that offer reproductive health care, including abortion and management of early pregnancy loss.
  • Permits the DOC to charge a $5 per dose fee (starting in 2026) to cover secure storage and delivery costs, and to sell medications at cost (not exceeding list price).
  • Exempts the DOC from needing a wholesaler’s license for distributing abortion medications under this law, as authorized by existing law (RCW 18.64.046).
  • Requires the DOC to coordinate with the Department of Health to identify appropriate recipients and prioritize bulk distribution to health care providers and entities.
  • Declares the bill an emergency, making it effective immediately upon passage—February 13, 2026.

Who is affected

  • Health care providers and health care entities (e.g., clinics, hospitals, pharmacies) — Can receive abortion medications directly from the state Department of Corrections (DOC) for use in providing reproductive health care, including abortion care and management of early pregnancy loss, especially in correctional facilities or through partnerships with community health providers.
  • Individuals seeking reproductive health care, including incarcerated people — May benefit from improved access to abortion medications through state-distributed programs, particularly those in custody or under DOC supervision, but also potentially others if the state chooses to expand access broadly.
  • Department of Health — Will coordinate with the DOC to identify appropriate recipients and support bulk distribution efforts, helping ensure equitable access across the state.
  • Department of Corrections — May collect a $5 per dose fee to cover secure storage and delivery costs, and must follow state pharmacy and distribution laws while exempt from needing a wholesaler’s license for this activity.
Effective: February 13, 2026Fiscal impact: The bill allows the Department of Corrections to charge a $5 per dose fee to cover secure storage and delivery costs; revenues from this fee (and any other sales) during the 2025 fiscal year are required to be deposited into the general fund.
Model: Intel/Qwen3-Coder-Next-int4-AutoRoundGenerated: Mar 20, 2026 at 2:26 AM

Pro/Con Analysis

Stronger case for benefits

Potential Benefits (5)

  • The bill significantly improves access to abortion medications for low-income, rural, and incarcerated individuals by enabling bulk state-distributed supply—potentially reducing travel, wait times, and out-of-pocket costs for people who otherwise face geographic or financial barriers to care.

    HealthcarePeopleRef: RCW 72.09.780(2), (4)(a), (5); NEW SECTION Sec. 2

  • By centralizing procurement and distribution through a state agency, the bill reduces reliance on private pharmaceutical supply chains vulnerable to shortages or politicized restrictions—enhancing supply reliability for community clinics and public health departments.

    Public SafetyPeopleRef: RCW 72.09.780(4)(a), (b); NEW SECTION Sec. 2

  • The state-distributed model may support housing-stable but underinsured individuals (e.g., those in transitional housing or shelters) who lack consistent access to reproductive health providers but qualify for state-distributed medications.

    HousingPeopleRef: RCW 72.09.780(4)(a), (b); NEW SECTION Sec. 2

  • Improved access to abortion medications may reduce unintended pregnancies among young adults, supporting continued enrollment and completion of postsecondary education—particularly for low-income and first-generation students.

    EducationPeopleRef: RCW 72.09.780(4)(a), (b); NEW SECTION Sec. 2

  • The $5 per dose fee (offsetting storage/delivery costs) and cost-of-sales pricing may help community clinics and public health departments reduce procurement costs compared to commercial wholesale markups—though savings depend on volume and logistics efficiency.

    FinancialLean peopleRef: RCW 72.09.780(4)(b) (fee structure), NEW SECTION Sec. 2
Potential Concerns (5)

  • The bill authorizes the Department of Corrections (DOC) to distribute controlled abortion medications outside the correctional system, raising concerns about diversion, misuse, or security breaches—especially given that DOC is not a traditional pharmaceutical distributor and lacks public health infrastructure oversight.

    Public SafetyLean peopleRef: RCW 72.09.780(4)(a), (b); NEW SECTION Sec. 2 (emergency clause)

  • The $5 per dose fee is capped at cost recovery, but the emergency effective date (Feb. 13, 2026) and lack of phased implementation may strain local health departments and community clinics with limited capacity to absorb and safely manage state-distributed abortion medications without additional training or support.

    Local GovernmentLean peopleRef: RCW 72.09.780(4)(b) (fee structure), NEW SECTION Sec. 2 (emergency effective date)

  • The bill’s broad authority to distribute to “any” health care provider or entity—including those not currently authorized to dispense abortion medications—may increase liability risk for small clinics or rural providers lacking protocols for safe storage, administration, and follow-up care.

    HealthcareLean peopleRef: RCW 72.09.780(4)(a) (distribution to any health care provider/entity), NEW SECTION Sec. 2

  • The $5 per dose fee is intended to cover secure storage and delivery, but the bill does not specify how costs are calculated or audited—raising risk that under-recovery could shift burden to other state programs, or over-recovery could price out low-income clinics.

    FinancialRef: RCW 72.09.780(4)(b) (fee structure), NEW SECTION Sec. 2

  • Exempting DOC from wholesaler licensing requirements may create regulatory ambiguity, especially if DOC contracts with third-party logistics providers—potentially undermining oversight of chain-of-custody, cold-chain integrity, and adverse event reporting.

    Business & EmploymentRef: RCW 72.09.780(3) (wholesaler license exemption), NEW SECTION Sec. 2

Who Is Most Affected

Low-income individuals and incarcerated peoplePositive Impact

Low-income individuals, especially those in rural areas or without insurance, are likely to benefit significantly from reduced cost and improved access to abortion medications via state-distributed supply. Incarcerated people may also benefit if DOC implements in-custody access—though current provisions do not mandate it.

Community health providers and clinicsMixed Impact

Community clinics, Planned Parenthood affiliates, and public health departments in underserved areas stand to gain reliable, low-cost supply—potentially expanding their capacity to provide reproductive care. However, small rural clinics may face logistical challenges without additional state support.

State agencies (DOC and DOH)Mixed Impact

The Department of Corrections gains expanded authority but must invest in secure logistics and compliance with pharmacy regulations. The Department of Health gains a partner for distribution but must coordinate oversight—potentially increasing interagency workload.

Commercial pharmaceutical distributors and pharmaciesNegative Impact

Commercial pharmacies and wholesalers may see reduced demand for abortion medications if state-distributed supply displaces private procurement—especially for bulk orders. However, the impact is likely modest given the niche nature of abortion medication distribution.

Rural health care facilitiesMixed Impact

Rural hospitals and federally qualified health centers (FQHCs) may benefit from improved supply reliability, but may lack storage infrastructure (e.g., refrigeration for mifepristone) without additional state support—limiting net benefit unless technical assistance is provided.